Site Suitability Template

* For Belgium, this form is a mandatory document to be submitted with Part II of the dossier.
* To minimise the number of Request For Information (RFIs) that could be raised during the process and possible rejection, kindly provide detailed and informative responses to each and every question at the best of your knowledge.
* When completing this form, any national guidelines should also be referred to with regards to which sections must be completed. Where no national guidelines exist, the form should be completed in full.
* Where information which is requested in this form is provided elsewhere in the application dossier, the document can just be referenced rather than repeating the information.
* A separate document should be completed and submitted for each site.

This template has been endorsed by the EU Clinical Trials Coordination and Advisory Group to comply with Regulation (EU) No. 536/2014 Clinical Trials on Medicinal Products for Human Use.

|  |  |
| --- | --- |
| Section 1 | |
| EU trial number |  |
| Title of clinical trial |  |
| Name of site[[1]](#footnote-1), city | Cliniques universitaires Saint-Luc (CUSL), Brussels |
| If applicable, unique identification number of the site[[2]](#footnote-2) | Belgian hospital approval number : 403  Official Belgian site number : 4190  Study site number : |
| Name of principal investigator |  |
| Planned number of trial participants at the site |  |

|  |
| --- |
| Section 2 |
| 1. *Please provide a comprehensive written statement on the suitability of the site adapted to the nature and use of the investigational medicinal product.* |
| Based on the nature and use of the Investigational Medical Product (IMP), the human resources, equipment and facilities are of sufficient quality and adequacy to conduct the clinical trial undertaken at site.  The pharmacy is equipped with room-temperature and refrigerated temperature-controlled storage facilities, protected from light, and a preparation area for intravenous investigational products that meets the protocol requirements for the preparation of investigational medicinal products.  Experimental products will be received and stored at the pharmacy, under continuous temperature monitoring, in a dedicated clinical trial area for: name of IMP(s).  IMP will be stored at room temperature 20°-25°C in a dedicated cupboard for clinical trial use, under continuous temperature monitoring (equipped with a min/max thermometer record). Thermometer is validated and calibrated.  IMP will be stored in a fridge at 2°-8°C under continuous  temperature monitoring (equipped with a min/max thermometer  record). Thermometer is validated and calibrated.  The ambient storage place and the fridge are dedicated for Clinical Trial use and stored in a secure area. In case of temperature excursion, an alarm will automatically inform the pharmacist  The IMP will be stored in accordance with protocol requirements.  The pharmacy of the Cliniques universitaires Saint-Luc is well-equipped and has all necessary material to conduct the name of the study study as per protocol requirements. Human resources is adequate and available to conduct the study. Our services are equipped and adapted to the investigational medicinal product of the study. |
| 1. *Please describe in detail the suitability of the facilities* |
| Cliniques universitaires Saint-Luc have all equipment, facilities and human resources to conduct the name of the study study as per protocol requirements.  Site has :   * name of departments/units involved in the study, radiology department, pathology department, pharmacy department, … * inpatient units, consultation rooms, and day hospitalization * storage areas for study materials (investigator binders, laboratory KITs, facilities for laboratory sample preparation) and offices dedicated to clinical research staff with computer, telephone, fax, printer and internet access * adequate storage areas for the study drug, with secure, limited access and temperature control. * room for CRAs to carry out monitoring visits, with access to an internet connection   Site is adequate and well equipped to perform all procedures required by the protocol. |
| 1. *Please describe accurately the suitability of the equipment* |
| The equipment required at the center is calibrated, checked, maintained and documented:  - a weigh scale ;  - a height gauge ;  - an automated blood pressure and pulse measurement device;  - thermometers;  - 12-electrode ECG;  - cardiac ultrasound;  - other ultrasound;  - magnetic resonance imaging;  - CT scanner;  - PET scanner;  - Muga scan;  - Scintigraphy;  - ophthalmology equipment for examination : list of equipment or examination  - pneumology equipment for examination : list of equipment or examination  - a local laboratory;  - emergency equipment;  - surgery rooms;  - a temperature-controlled refrigerator at 4°C;  - a temperature-controlled freezer at -20°C ± 5°C;  - a temperature-controlled freezer at -80°C;  - a temperature-controlled centrifuge;  - a room temperature centrifuge. |
| 1. *Please provide a detailed description of all trial procedures which will take place at the site.* |
| All study procedures can be performed at site:   * Collect of ICF * Follow-up of the patients by the investigator (PI and sub) and study coordinator * Procedures regarding IMP * All procedures detailed in protocol : list of procedures according to the protocol (cfr flowchart). |
| 1. *Please provide a detailed description of Human Resources arrangements and expertise at the site* |
| The PI has sufficient human resources (including back-ups) in order to conduct the trial effectively:   * PI: name of the PI * Sub-investigators: Number * Study-coordinators/study-nurses and Back-up: Number   The work of study coordinators is taken over by nurses and scientists to cover all the aspects of the study.   * Pharmacists for clinical research: 4   All our study staff is qualified to conduct the trial, and have the appropriate training and experience to carry out the tasks assigned to them within the framework of the trial. All the staff involved in clinical research is GCP (Transcelerate) certified since less than 3 years. People involved in samples management and shipping are IATA certified (less than 2 years)  The site and the principal investigator have a good potential for eligible patients and have extensive experience in clinical trials.  The principal investigator, name, MD, PhD has more than xx years experience in  speciality clinical trials, phases I, II, III and IV.  The CUSL has an university emergency and ICU department being able to follow the safety issues.  The radiology department also has radiologists trained in interventional radiology.  The laboratory is accredited by BELAC and Sciensano. The internal biobank is accredited by the FAHMP.  All the hospital department including radiology, laboratory, pharmacy are working on a 24/24 hours -7/7 days basis.  One-day clinic and hospitalization units are available with experienced staff in clinical research.  The CUSL Clinical Trial Center is managing centrally the submissions preparation, the contracts, the initial and continuous training of the study coordinators, the quality management system for clinical research  The Cliniques universitaires Saint Luc are AAHRPP accredited since 2015 (renewed in 2023 for 5 more years).  The EMR (EPIC) used as source data is built to track and follow research patients, to allow specific accesses and to protect data. |

|  |
| --- |
| Section 3 |
| In authorising this document, I confirm that the site has the facilities and equipment to be able to conduct the clinical trial and has suitable arrangements in place to ensure that all investigators and other individuals involved in conducting the trial have the suitable qualifications, expertise and training in relation to their role in the clinical trial, in compliance with EU Regulation 536/2014, and all conditions identified, which might influence the impartiality of any investigators, were addressed.  Issued by:  Name: Jean-Louis Vanoverschelde.  Position: Medical director.  On behalf of the site/organisation[[3]](#footnote-3)  Date[[4]](#footnote-4):  Signature:  Please ensure that you have consulted with any national guidelines before submitting this form |

*PI signature for acknowledgement (CuSL requirement)*

*Name :*

*Date :*

*Signature :*

1. For BE: If it does not concern a healthcare institution, mention the name of the Private organisation. [↑](#footnote-ref-1)
2. For BE: Mention the “Erkenningsnummer van het ziekenhuis” / “Numéro d'agrément de l’hôpital” as given in the list of the [FPS Public Health (belgium.be)](https://www.health.belgium.be/en/node/25589) and which are registered in CTIS. If the CEO of different hospital sites is the same, the sites can be listed in one statement. [↑](#footnote-ref-2)
3. For BE: The person signing the document is authorised to sign on behalf of the site/organisation. [↑](#footnote-ref-3)
4. The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation. For Belgium, this document must be signed in the clinical trial application. [↑](#footnote-ref-4)